---
schema_version: "secwatch.filing_event.v1"
accession: "0001096906-23-002316"
form_type: "8-K"
ticker: "AIBT"
cik: "0001763329"
company_name: "AIBOTICS, INC."
filed_at: "2023-12-05T23:59:59+00:00"
generated_at: "2026-06-07T18:08:50.380319+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Mycotopia Therapies acquires AI robotics assets from Philon Labs; up to $9M in stock, to rename AiBotics

## Summary
- Acquires patents for Phill Robot (AI massage robot) and Milky Way (smart breast-milk fridge) from Philon Labs.
- Issues $2M face-value convertible preferred stock; up to $7M more preferred stock tied to revenue incentives over 3 years.
- Philon Labs CEO David Gruszka to become President of Mycotopia Therapies.
- Company plans to change name to AiBotics and ticker to ABIT, pending FINRA approval.
- Press release issued December 4, 2023 announcing the transaction.

## SEC filing metadata
- accession: 0001096906-23-002316
- form_type: 8-K
- ticker: AIBT
- cik: 0001763329
- company_name: AIBOTICS, INC.
- filed_at: 2023-12-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763329/000109690623002316/0001096906-23-002316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763329/000109690623002316/tpia-20231128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001096906-23-002316
- JSON: https://secwatch.observer/filing/0001096906-23-002316.json
- Plain text: https://secwatch.observer/filing/0001096906-23-002316.txt

## Key facts
- M&A Transactions
  AIBOTICS, INC. completed an acquisition involving Philon Labs, LLC for Preferred Stock with a face value of $2,000,000 (closed 2023-11-28).
  - Action: acquisition
  - Counterparty: Philon Labs, LLC
  - Consideration: Preferred Stock with a face value of $2,000,000
  - Closing: 2023-11-28
  source text: Way” products. In consideration for the acquisition of the Assets, Mycotopia Therapies will issue a new class of Preferred Stock (the “Preferred Stock”) with a face value of $2,000,000, convertible into shares of the Company’s Common Stock (the “Common Stock”). All shares of Preferred Stock and Common Stock issued in conjunction with the transaction will be
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763329/000109690623002316/0001096906-23-002316-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.